Illumina (ILMN)
NASDAQ:ILMN
Want to see ILMN full AI Analyst Report?
ILMN Stock Chart & Stats
$134.50
-$1.43(-1.02%)
At close: 4:00 PM EST
$134.50
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$73.86 - $155.53
Previous CloseN/A
Volume388.94K
Average Volume (3M)1.42M
Market Cap
$21.17B
Enterprise Value$22.55B
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$2.46B
Price to Earnings (P/E)34.5
Beta1.24
Next Earnings
Aug 06, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.54
Shares Outstanding151,906,920
10 Day Avg. Volume1,461,192
30 Day Avg. Volume1,422,964
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue5.13
Enterprise Value/Gross Profit7.59
Enterprise Value/Ebitda18.59
Forecast
1Y Price Target
$140.36Price Target Upside4.36% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)5.2
Revenue Forecast (FY)$4.56B
Bulls Say, Bears Say
Bulls Say
China Recovery And International PlacementsEasing of import restrictions and improved regulatory engagement in China combined with stronger instrument placements outside China supports revenue recovery and consumables growth.
Clinical And Multiomics AdoptionAnalyst notes that emphasis on clinical and multiomics products is expected to increase consumables usage and drive meaningful volume growth among clinical customers.
Platform Transition And Consumables DemandCompletion of the transition to the NovaSeq X platform should raise sequencing throughput, reduce pricing pressure, and support higher consumables revenue per instrument.
Bears Say
Competitive Threat From Roche's AXELIOSRoche's AXELIOS platform and reusable chip model present a credible clinical alternative that could capture share from established sequencers.
Pricing Pressure From Low-cost CompetitorsMultiple rivals introducing lower-cost, high-throughput sequencers could intensify pricing competition and pressure margins for core sequencing products.
Weak Backlog And Demand SoftnessPersistently low backlog levels and muted research demand may prolong evaluation cycles, slow ordering, and create downside risk to company guidance.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $73.86 and its highest was $155.53 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $21.17B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Aug 06, 2026 which is in 92 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Apr 30, 2026. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.055 by $0.095.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.23.
How many shares outstanding does Illumina have?
Illumina has 151,906,920 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.15 in its last earnings report, beating expectations of $1.055. Following the earnings report the stock price went up 7.133%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$140.36 (4.36% Upside)
$140.36 (4.36% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 251.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $558.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.90%
12-Months-Change
Fundamentals
Return on Equity
34.94%
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
ILMN Company Deck
ILMN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a clear beat in Q1 with multiple key operational and financial positives: revenue and EPS outperformance, strong clinical consumables growth (~20% ex-China), robust NovaSeq X placements (80+ in the quarter), margin expansion, and an upwardly revised full-year guide. Offsetting items include continued weakness in research & applied consumables (down ~12% ex-China), a 20% decline in microarrays RoW organic, supply constraints on NovaSeq X that require scaling investments, and near-term inflationary pressures impacting Q2 margins. Management framed the negatives as transitory or manageable and emphasized product innovation, strong cash flow, and progress toward 2027 targets.View all ILMN earnings summariesILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILMN Stock 12 Month Forecast
Average Price Target
$140.36
▲(4.36% Upside)
Technical Analysis
Ownership Overview
2.84% Insiders
28.29% Mutual Funds
3.94% Other Institutional Investors
41.06% Public Companies and
Individual Investors